Evaluation of molecular breast imaging in women undergoing myocardial perfusion imaging with Tc-99m sestamibi

Carrie B Hruska, Deborah Rhodes, Douglas A. Collins, Cindy L. Tortorelli, J. Wells Askew, Michael K. O'Connor

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Our objective was to explore the potential benefits of molecular breast imaging (MBI) as a screening technique in women undergoing stress myocardial perfusion studies. Methods: MBI was offered to women receiving Tc-99m sestamibi injection for myocardial perfusion stress testing. During the required waiting period after stress isotope injection, MBI was performed using a dedicated breast imaging gamma camera system. MBI examinations were interpreted by breast radiologists, with review of a recent mammogram in cases with positive MBI. Results: Of 322 women enrolled, 313 completed MBI, comprising 5 with known breast cancer, 2 with known high-risk benign breast lesions, and 306 who were asymptomatic for breast disease with a recent negative mammogram. Analysis was limited to the 306 patients with no known breast disease. MBI was positive in 22 of 306, giving a recall rate of 7.2% (95% confidence interval [CI] 4.8-10.6]. MBI detected 4 new cancers, resulting in a supplemental diagnostic yield of 13.1/1000 women screened (95% CI 5.1-33.2). The number of cancers diagnosed per abnormal MBI examinations (PPV 1) was 18% (4 of 22) (95% CI 7.3-38.5), and the number diagnosed per MBI-prompted biopsies (PPV 3) was 44% (4 of 9) (95% CI 18.9-73.3). Conclusions: The addition of MBI to clinically indicated stress myocardial perfusion imaging studies in women results in a high diagnostic yield of newly detected breast cancers while generating a low rate of additional unnecessary workup.

Original languageEnglish (US)
Pages (from-to)730-738
Number of pages9
JournalJournal of Women's Health
Volume21
Issue number7
DOIs
StatePublished - Jul 1 2012

Fingerprint

Myocardial Perfusion Imaging
Molecular Imaging
Breast
Confidence Intervals
Breast Diseases
Perfusion
Breast Neoplasms
Asymptomatic Diseases
Injections
Isotopes
Radionuclide Imaging

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Evaluation of molecular breast imaging in women undergoing myocardial perfusion imaging with Tc-99m sestamibi. / Hruska, Carrie B; Rhodes, Deborah; Collins, Douglas A.; Tortorelli, Cindy L.; Askew, J. Wells; O'Connor, Michael K.

In: Journal of Women's Health, Vol. 21, No. 7, 01.07.2012, p. 730-738.

Research output: Contribution to journalArticle

Hruska, Carrie B ; Rhodes, Deborah ; Collins, Douglas A. ; Tortorelli, Cindy L. ; Askew, J. Wells ; O'Connor, Michael K. / Evaluation of molecular breast imaging in women undergoing myocardial perfusion imaging with Tc-99m sestamibi. In: Journal of Women's Health. 2012 ; Vol. 21, No. 7. pp. 730-738.
@article{d6896089902e42c4949856cc1863c4e1,
title = "Evaluation of molecular breast imaging in women undergoing myocardial perfusion imaging with Tc-99m sestamibi",
abstract = "Background: Our objective was to explore the potential benefits of molecular breast imaging (MBI) as a screening technique in women undergoing stress myocardial perfusion studies. Methods: MBI was offered to women receiving Tc-99m sestamibi injection for myocardial perfusion stress testing. During the required waiting period after stress isotope injection, MBI was performed using a dedicated breast imaging gamma camera system. MBI examinations were interpreted by breast radiologists, with review of a recent mammogram in cases with positive MBI. Results: Of 322 women enrolled, 313 completed MBI, comprising 5 with known breast cancer, 2 with known high-risk benign breast lesions, and 306 who were asymptomatic for breast disease with a recent negative mammogram. Analysis was limited to the 306 patients with no known breast disease. MBI was positive in 22 of 306, giving a recall rate of 7.2{\%} (95{\%} confidence interval [CI] 4.8-10.6]. MBI detected 4 new cancers, resulting in a supplemental diagnostic yield of 13.1/1000 women screened (95{\%} CI 5.1-33.2). The number of cancers diagnosed per abnormal MBI examinations (PPV 1) was 18{\%} (4 of 22) (95{\%} CI 7.3-38.5), and the number diagnosed per MBI-prompted biopsies (PPV 3) was 44{\%} (4 of 9) (95{\%} CI 18.9-73.3). Conclusions: The addition of MBI to clinically indicated stress myocardial perfusion imaging studies in women results in a high diagnostic yield of newly detected breast cancers while generating a low rate of additional unnecessary workup.",
author = "Hruska, {Carrie B} and Deborah Rhodes and Collins, {Douglas A.} and Tortorelli, {Cindy L.} and Askew, {J. Wells} and O'Connor, {Michael K.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1089/jwh.2011.3267",
language = "English (US)",
volume = "21",
pages = "730--738",
journal = "Journal of women's health (2002)",
issn = "1540-9996",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Evaluation of molecular breast imaging in women undergoing myocardial perfusion imaging with Tc-99m sestamibi

AU - Hruska, Carrie B

AU - Rhodes, Deborah

AU - Collins, Douglas A.

AU - Tortorelli, Cindy L.

AU - Askew, J. Wells

AU - O'Connor, Michael K.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Background: Our objective was to explore the potential benefits of molecular breast imaging (MBI) as a screening technique in women undergoing stress myocardial perfusion studies. Methods: MBI was offered to women receiving Tc-99m sestamibi injection for myocardial perfusion stress testing. During the required waiting period after stress isotope injection, MBI was performed using a dedicated breast imaging gamma camera system. MBI examinations were interpreted by breast radiologists, with review of a recent mammogram in cases with positive MBI. Results: Of 322 women enrolled, 313 completed MBI, comprising 5 with known breast cancer, 2 with known high-risk benign breast lesions, and 306 who were asymptomatic for breast disease with a recent negative mammogram. Analysis was limited to the 306 patients with no known breast disease. MBI was positive in 22 of 306, giving a recall rate of 7.2% (95% confidence interval [CI] 4.8-10.6]. MBI detected 4 new cancers, resulting in a supplemental diagnostic yield of 13.1/1000 women screened (95% CI 5.1-33.2). The number of cancers diagnosed per abnormal MBI examinations (PPV 1) was 18% (4 of 22) (95% CI 7.3-38.5), and the number diagnosed per MBI-prompted biopsies (PPV 3) was 44% (4 of 9) (95% CI 18.9-73.3). Conclusions: The addition of MBI to clinically indicated stress myocardial perfusion imaging studies in women results in a high diagnostic yield of newly detected breast cancers while generating a low rate of additional unnecessary workup.

AB - Background: Our objective was to explore the potential benefits of molecular breast imaging (MBI) as a screening technique in women undergoing stress myocardial perfusion studies. Methods: MBI was offered to women receiving Tc-99m sestamibi injection for myocardial perfusion stress testing. During the required waiting period after stress isotope injection, MBI was performed using a dedicated breast imaging gamma camera system. MBI examinations were interpreted by breast radiologists, with review of a recent mammogram in cases with positive MBI. Results: Of 322 women enrolled, 313 completed MBI, comprising 5 with known breast cancer, 2 with known high-risk benign breast lesions, and 306 who were asymptomatic for breast disease with a recent negative mammogram. Analysis was limited to the 306 patients with no known breast disease. MBI was positive in 22 of 306, giving a recall rate of 7.2% (95% confidence interval [CI] 4.8-10.6]. MBI detected 4 new cancers, resulting in a supplemental diagnostic yield of 13.1/1000 women screened (95% CI 5.1-33.2). The number of cancers diagnosed per abnormal MBI examinations (PPV 1) was 18% (4 of 22) (95% CI 7.3-38.5), and the number diagnosed per MBI-prompted biopsies (PPV 3) was 44% (4 of 9) (95% CI 18.9-73.3). Conclusions: The addition of MBI to clinically indicated stress myocardial perfusion imaging studies in women results in a high diagnostic yield of newly detected breast cancers while generating a low rate of additional unnecessary workup.

UR - http://www.scopus.com/inward/record.url?scp=84863687336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863687336&partnerID=8YFLogxK

U2 - 10.1089/jwh.2011.3267

DO - 10.1089/jwh.2011.3267

M3 - Article

C2 - 22404787

AN - SCOPUS:84863687336

VL - 21

SP - 730

EP - 738

JO - Journal of women's health (2002)

JF - Journal of women's health (2002)

SN - 1540-9996

IS - 7

ER -